Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 3/20 | 0.31 |
| ▸ | CCND1 | P24385 | 3/20 | 0.31 |
| ▸ | CCND3 | P30281 | 3/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21522800 | 0.88 | CDK4 (0.41) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL2511865 | 0.84 | CDK4 (0.36) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL29403292 | 0.84 | CDK4 (0.36) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL20987201 | 0.81 | LPL (0.31) | LPLLIPGIRAK4 | |
| SCHEMBL21522812 | 0.81 | CDK4 (0.40) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL19836734 | 0.81 | ROCK1 (0.32) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL21522778 | 0.81 | CDK4 (0.40) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL21522780 | 0.81 | CDK4 (0.40) | LPLLIPGCDK4CCND1CCND3 | |
| SCHEMBL30926519 | 0.81 | LPL (0.31) | LPLLIPGIRAK4 | |
| SCHEMBL26454127 | 0.81 | ROCK1 (0.32) | LPLLIPGCDK4CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020135507-A1 | POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | 杭州百新生物医药科技有限公司 | 2020-07-02 | — | — | WO | disclosed |